MD Anderson doubles up on cancer 'Moon Shots'

MD Anderson, which has attracted a who's who in immuno-oncology as partners for its Moon Shots R&D program, is adding 6 new cancers to its list of targets. The research institution is doubling down on its moon shots, adding B-cell lymphomas, glioblastoma, HPV, multiple myeloma, colorectal and pancreatic cancers to the list. "As the Moon Shots Program matures, we're transitioning from the foundational phase to the results phase, and some moon shots already are making practice-changing advances in the clinic and in cancer prevention and control," says MD Anderson's Ronald DePinho. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.